Spero Therapeutics (NASDAQ:SPRO) Stock: Insider Esther Rajavelu Sells 40,851 Shares

Posted by Geri Gentry on Nov 10th, 2026

Spero Therapeutics, Inc. (NASDAQ:SPRO – Get Free Report) insider Esther Rajavelu sold 40,851 shares of Spero Therapeutics stock in a transaction that occurred on Monday, November 9th. The shares were sold at an average price of $1.04, for a total transaction of $42,485.04. Following the sale, the insider owned 946,000 shares of the company’s stock, valued at approximately $983,840. The trade was a 4.14% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Spero Therapeutics Trading Down 5.6%

Shares of SPRO traded down $0.06 during midday trading on Tuesday, reaching $1.01. The stock had a trading volume of 183,743 shares, compared to its average volume of 782,123. The company’s 50-day moving average is $1.15 and its 200 day moving average is $1.94. Spero Therapeutics, Inc. has a 12-month low of $0.96 and a 12-month high of $3.08. The company has a market capitalization of $58.82 million, a price-to-earnings ratio of 9.18 and a beta of 1.59.

Spero Therapeutics (NASDAQ:SPRO – Get Free Report) last issued its earnings results on Wednesday, August 12th. The company reported ($0.16) EPS for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.01. Spero Therapeutics had a net margin of 24.90% and a return on equity of 16.17%. Research analysts forecast that Spero Therapeutics, Inc. will post -0.97 EPS for the current fiscal year.

Analyst Ratings Changes

Several research firms have weighed in on SPRO. Cantor Fitzgerald started coverage on Spero Therapeutics in a research report on Wednesday, October 28th. They set an “overweight” rating and a $6.00 price objective on the stock. Zacks Research upgraded Spero Therapeutics to a “hold” rating in a research note on Monday, September 14th. Weiss Ratings cut Spero Therapeutics from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Monday, October 26th. Wall Street Zen downgraded Spero Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, October 31st. Finally, HC Wainwright increased their price objective on Spero Therapeutics from $5.00 to $6.00 and gave the stock a “buy” rating in a report on Monday, September 14th. Two analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $6.00.

View Our Latest Research Report on Spero Therapeutics

Hedge Funds Weigh In On Spero Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the business. Alphabet Inc. bought a new position in shares of Spero Therapeutics in the second quarter worth approximately $1,967,000. BlackRock Inc. bought a new stake in shares of Spero Therapeutics in the second quarter worth $1,314,000. GSA Capital Partners LLP bought a new position in Spero Therapeutics in the second quarter worth approximately $632,000. Global Retirement Partners LLC bought a new position in Spero Therapeutics in the 2nd quarter worth $55,000. Finally, Susquehanna Fundamental Investments LLC purchased a new position in shares of Spero Therapeutics during the 2nd quarter valued at about $36,000. Institutional investors own 25.60% of the company’s stock.

Spero Therapeutics Company Profile

(Get Free Report)

Spero Therapeutics, Inc. (NASDAQ:SPRO) is a biopharmaceutical company focused on developing treatments for multidrug-resistant bacterial infections and certain rare diseases. The company’s research programs are designed to address infections for which existing antibiotics may be inadequate, including complicated urinary tract infections and infections caused by difficult-to-treat pathogens. Spero’s lead product candidate has been tebipenem pivoxil hydrobromide, an orally administered carbapenem antibiotic developed for the treatment of complicated urinary tract infections.